A new LSD-derived compound called JRT shows promise for treating schizophrenia and other brain disorders without inducing hallucinations. Developed by researchers who altered just two atoms in LSD’s structure, JRT maintains the psychedelic’s neuroplastic effects while avoiding its psychosis-linked risks.
